Built Like a Fingerprint: Scientists Unveil Breakthrough Cancer Vaccine

● How mRNA vaccine Slashesd Melanoma Spread By 59% in Landmark Trial

Hope just got a new name in oncology: personalised.
Scientists from Merck and Moderna have reported a major breakthrough — an mRNA cancer vaccine that helped prevent melanoma from coming back or spreading in a large trial of more than 1,000 patients.

The vaccine, called _intismeran autogene_, is not a one-size-fits-all drug. It is built like a fingerprint, designed around the unique mutations of each patient’s tumour after surgery.

For years, cancer treatment has felt like using a sledgehammer. Chemotherapy kills everything in its path — cancerous and healthy alike. This new approach is more like a guided missile: it trains your own immune system to hunt only the cells with your cancer’s signature.

The treatment works in two parts. Patients receive up to nine doses of Merck’s immunotherapy drug, Keytruda, every six weeks. Alongside it, they get up to nine doses of a custom mRNA vaccine created just for them.

Merck describes it as an “mRNA-based individualised neoantigen therapy.” In plain language: scientists read the DNA of a patient’s removed tumour, identify up to 34 unique neoantigens — flags on cancer cells — and code synthetic mRNA to teach the immune system to attack them.

Neoantigens are the cancer’s tell-tale scars. And melanoma, which is notorious for carrying many mutations, turned out to be the perfect first target.

According to the US National Cancer Institute, melanoma is less common than other skin cancers but far deadlier. It spreads faster, invades deeper, and causes most skin cancer deaths. The American Cancer Society estimates about 112,000 new invasive melanoma cases and 8,510 deaths in the US alone in 2026.

The numbers from the trial are what made researchers sit up. Five-year data from the Phase 2b study showed that adding intismeran autogene to Keytruda cut the risk of cancer returning or death by 49 per cent compared to Keytruda alone.

The benefit was even sharper for metastasis. The combination reduced the risk of the cancer spreading to distant parts of the body or death by 59 per cent, Merck said.

“With this positive study, there is hope,” said Dr. Ryan Sullivan, director of the Centre for Melanoma at Mass General Brigham Cancer Institute. He called the findings “a big deal for the field in general,” telling Reuters the approach could change how cancer is treated broadly.

Dr. Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology, went further. She described the results as “a monumental leap forward” and said they validate mRNA technology — the same platform behind COVID-19 vaccines — as a real cancer treatment.

The momentum is already leaving melanoma behind. Moderna and Merck are now testing the same personalised approach in non-small cell lung cancer, bladder cancer, kidney cancer, and even in pancreatic and stomach cancers. Results from several of those trials are expected in the next one to two years, according to Moderna President Stephen Hoge.

They are not alone in the race. Roche and BioNTech are also testing a similar mRNA vaccine, _autogene cevumeran_, in colon and pancreatic cancer patients after surgery. “We should be hearing results from multiple studies over the next few years, and there’s every reason to hope now,” said Dr. Robert Vonderheide, president-elect of the American Association for Cancer Research.

Caution remains. The current melanoma trial is still ongoing. Researchers have not released full data yet, and they are continuing to follow patients to see if the vaccine also extends overall survival. The treatment is not yet approved for general use.

Still, for patients staring down high-risk melanoma, the message has shifted. For the first time, science is offering a vaccine that isn’t to prevent a virus — but to prevent _your_ cancer from coming back. In a field long defined by blunt tools, that feels less like incremental progress and more like a new chapter.

Platforms Africa